MARKET

XNCR

XNCR

Xencor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.02
+0.75
+2.40%
After Hours: 32.02 0 0.00% 16:00 07/14 EDT
OPEN
31.29
PREV CLOSE
31.27
HIGH
32.03
LOW
30.98
VOLUME
348.70K
TURNOVER
--
52 WEEK HIGH
46.33
52 WEEK LOW
19.35
MARKET CAP
1.83B
P/E (TTM)
-29.6317
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XNCR stock price target is 44.17 with a high estimate of 56.00 and a low estimate of 21.00.

EPS

XNCR News

More
Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
GlobeNewswire · 6d ago
Atreca teams up with Xencor to develop T cell engaging antibodies
Seeking Alpha - Article · 6d ago
Xencor and Atreca Enter Strategic Collaboration To 'Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies'
MONROVIA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and
Benzinga · 6d ago
Were Hedge Funds Right About Selling Xencor Inc (XNCR)?
Insider Monkey · 06/30 16:30
Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the presentation of new preclinical data from three XmAb® 2+1 bispecific an
Business Wire · 06/22 13:06
Edited Transcript of XNCR earnings conference call or presentation 7-May-20 8:30pm GMT
Q1 2020 Xencor Inc Earnings Call
Thomson Reuters StreetEvents · 06/08 17:48
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28)
Benzinga · 05/29 11:22
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will par
Business Wire · 05/26 20:01

Industry

Biotechnology & Medical Research
+2.53%
Pharmaceuticals & Medical Research
+1.66%

Hot Stocks

Symbol
Price
%Change

About XNCR

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
More

Webull offers kinds of Xencor Inc stock information, including NASDAQ:XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.